Platform study of genotyping-guided precision medicine for rare solid tumours: a study protocol for a phase II, non-randomised, 18-month, open-label, multiarm, single-centre clinical trial testing the safety and efficacy of multiple Chinese-approved targeted drugs and PD-1 inhibitors in the treatment of metastatic rare tumours

INTRODUCTION: Limited clinical studies have been conducted on rare solid tumours, and there are few guidelines on the diagnosis and treatment, including experiences with targeted therapy and immunotherapy, of rare solid tumours in China, resulting in limited treatment options and poor outcomes. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Shuhang, Huang, Hui-Yao, Wu, Dawei, Fang, Hong, Ying, Jianming, Bai, Ying, Yu, Yue, Fang, Yuan, Jiang, Ning, Sun, Chao, Yu, Anqi, Fan, Qi, Xing, Shujun, Ni, Yufen, Zhang, Wei, Wu, Chenhua, Ji, Xinqian, Wang, Hui, Guo, Yaqian, Tang, Qiyu, Wang, Yuan, Tang, Yu, Li, Ning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183209/
https://www.ncbi.nlm.nih.gov/pubmed/34083331
http://dx.doi.org/10.1136/bmjopen-2020-044543

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183209/
https://www.ncbi.nlm.nih.gov/pubmed/34083331
http://dx.doi.org/10.1136/bmjopen-2020-044543

Ejemplares similares